Last reviewed · How we verify
NCT05670821
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
trial testing Spesolimab in Generalized Pustular Psoriasis in 52 participants. Completed in 6 October 2025.
6 October 2025
Quick facts
| Lead sponsor | Boehringer Ingelheim |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 52 |
| Start date | 18 April 2023 |
| Primary completion | 6 October 2025 |
| Estimated completion | 6 October 2025 |
| Sites | 1 location across Japan |
Drugs / interventions tested
- Spesolimab (SPESOLIMAB) — full drug profile →
Conditions studied
- Generalized Pustular Psoriasis — all drugs for Generalized Pustular Psoriasis →
Sponsor
Boehringer Ingelheim — full company profile →
Who can join
18 and older, any sex, with Generalized Pustular Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Spesolimab for the Treatment of Generalized Pustular Psoriasis.
Bernardo D, Thaçi D, Torres T. · · 2024 · cited 22× · PMID 38114719 · DOI 10.1007/s40265-023-01988-0 -
Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.
Gwillim EC, Nichols AJ. · · 2024 · cited 8× · PMID 39104539 · DOI 10.3389/fimmu.2024.1359481 -
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
Puig L, Fujita H, Thaçi D, Zheng M, et al · · 2024 · cited 8× · PMID 39088126 · DOI 10.1007/s13555-024-01230-z -
New and Emerging Treatments for Generalized Pustular Psoriasis: Focus on IL-36 Receptor Inhibitors.
Vilaça J, Yilmaz O, Torres T. · · 2024 · cited 5× · PMID 39065604 · DOI 10.3390/pharmaceutics16070908
Verify or expand the search:
- PubMed search for NCT05670821
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Spesolimab
Trials testing the same drug.
- NCT06624670 — A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum · Phase 3 · recruiting
- NCT06520514 — A Study to Test How Well Healthy People Tolerate Spesolimab When Given in 2 Different Ways · Phase 1 · completed
- NCT06241573 — A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurat · Phase 2, PHASE3 · terminated
- NCT06013969 — A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeate · Phase 4 · active not recruiting
- NCT06092216 — Spesolimab in Pyoderma Gangrenosum · Phase 2 · terminated
Other recruiting trials for Generalized Pustular Psoriasis
Currently open trials in the same condition.
- NCT06477536 — Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis · Phase 2, PHASE3 · recruiting
- NCT06323356 — A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
- NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
- NCT06013969 — A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeate · Phase 4 · active not recruiting
- NCT03886246 — Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Too · Phase 2 · active not recruiting
Other Boehringer Ingelheim trials
Trials by the same sponsor.
- NCT07044700 — Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection · not yet recruiting
- NCT07047508 — Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure a · not yet recruiting
- NCT07366034 — A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With I · Phase 3 · not yet recruiting
- NCT07531628 — A Study to Test How Verducatib is Taken up in the Body of Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07497087 — A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05670821 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boehringer Ingelheim
- Last refreshed: 20 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05670821.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing